Together we’re better

Patient Focused Tele-Health, LLC is actively seeking the correct industry partners to License (exclusively or non-exclusively) our proprietary Advanced Penetration Technology™ platform. PFTH has no doubt as to the dramatically improved efficacy, created by utilizing the APT™ platform, within non-prescription (OTC) categories of topical therapeutics. We also believe the APT™ will enhance any prescription topical product that has the correct chemical structure.

The ability to take existing, approved product platforms and create a category leading product can transform the market specific opportunities on a global scale.

Example: A highly effective, Non-Prescription therapy for Nail Fungal infections. Currently a global market opportunity of $3.1 billion, with a CAGR of 8.3%1. Regardless of other product claims, we have seen our Terbinafine 1% ointment effectively clear nail fungal infections in weeks, not months.

The proof is in the results

Currently PFTH has studies in progress for further validation of the efficacy of our Tetracycline 3% ointment on the most pathogenic and resistant bacteria in medicine. This information will be available by 5/2019.

PFTH also has a nail penetration study ongoing with results available in 4/2019. This will substantiate the penetration ability of the APT™ platform in delivering medications down deep into keratin and disrupted keratin.

1 Global Market Study on Dermatophytic Oncychomycosis Therapeutics (DOT): January 18, 2016. Persistence Market Research: 305 Broadway, 7th Floor New York City, NY. 10007

Give us a call or send us an email today to learn more about how we can work with you.

COVID-19 and APT™ T3X Formulation

COVID-19 (Coronavirus) is a PANDEMIC with no immediate vaccines, treatments and widespread diagnostics available. The USA and World health providers, pharmaceutical companies and governments are actively working to fund these vital initiatives.  “Social distancing” with its associated shutdown of commerce and normal routine appears to be the best solution so far in PREVENTING the spread of the COVID virus and associated suffering and mortality. The loss of life once a patient goes on a ventilator is frightening.

As the administration and American leaders have stated, that “economic shutdown” and “repeat of a shutdown”, cannot endure. Advanced Penetration Technology, LLC strongly believes the proprietary APT™ based NON-PRESCRIPTION (OTC) Topical formulation, used off-label, will play an important role in mitigating, decreasing and preventing the spread and severity of COVID-19 illness.

The Advanced Penetration Technology, LLC recommends the use of APT™ T3X formulation as a tool to mitigate the COVID-19 virus based upon recent and ongoing anti-viral studies.

Recently concluded Anti-Viral Studies demonstrated the significant efficacy of the APT™ T3X formulation in neutralizing the Influenza A virus (H1N1) and Coronavirus (NL63).   The laboratory conclusion was “Under the conditions tested, treatment of influenza A/WSN/33 virus and Coronavirus NL63, with APT™ T3X formulation abolishes infectivity”.  Further USA based viral testing is ongoing.  PFTH, LLC believes APT™ T3X formulation will neutralize infectivity of all viruses.

Decreasing the Viral Load of Exposure is the key to slowing and mitigating the spread of COVID-19 virus. The daily use of APT™ T3X formulation as a nasal swab application will help in the mitigation of the COVID-19 Pandemic.

Using ATP™ T3X and reasonable CDC guidelines, Grandparents should be able to hug their grandchildren, Worshipers should be able to attend church services, Students should be able to get back into schools and colleges, and the lifeblood of the US, our Economy, should keep moving forward.

Buy Now

Let's Stay In Touch

For tips and offers from us, enter your email and click the subscribe button below.